| General Information | |
|---|---|
| ZINC ID | ZINC000013742559 |
| Molecular Weight (Da) | 477 |
| SMILES | Cc1c(C(=O)c2cccc3ccccc23)c2ccc(Br)cc2n1CCN1CCOCC1 |
| Molecular Formula | C26Br1N2O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.564 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| LogP | 5.272 |
| Activity (Ki) in nM | 10 |
| Polar Surface Area (PSA) | 34.47 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.131 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.27 |
| Ilogp | 4.24 |
| Xlogp3 | 5.28 |
| Wlogp | 5.05 |
| Mlogp | 3.44 |
| Silicos-it log p | 5.8 |
| Consensus log p | 4.76 |
| Esol log s | -6.25 |
| Esol solubility (mg/ml) | 0.000269 |
| Esol solubility (mol/l) | 0.00000056 |
| Esol class | Poorly sol |
| Ali log s | -5.75 |
| Ali solubility (mg/ml) | 0.000841 |
| Ali solubility (mol/l) | 0.00000176 |
| Ali class | Moderately |
| Silicos-it logsw | -8.68 |
| Silicos-it solubility (mg/ml) | 0.00000099 |
| Silicos-it solubility (mol/l) | 2.09E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.46 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.19 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.21 |
| Logd | 4.252 |
| Logp | 5.476 |
| F (20%) | 0.006 |
| F (30%) | 0.028 |
| Mdck | - |
| Ppb | 97.53% |
| Vdss | 2.609 |
| Fu | 1.16% |
| Cyp1a2-inh | 0.709 |
| Cyp1a2-sub | 0.818 |
| Cyp2c19-inh | 0.761 |
| Cyp2c19-sub | 0.097 |
| Cl | 4.47 |
| T12 | 0.006 |
| H-ht | 0.455 |
| Dili | 0.928 |
| Roa | 0.721 |
| Fdamdd | 0.318 |
| Skinsen | 0.15 |
| Ec | 0.003 |
| Ei | 0.024 |
| Respiratory | 0.242 |
| Bcf | 1.969 |
| Igc50 | 5.026 |
| Lc50 | 6.348 |
| Lc50dm | 6.841 |
| Nr-ar | 0.061 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.888 |
| Nr-aromatase | 0.485 |
| Nr-er | 0.318 |
| Nr-er-lbd | 0.012 |
| Nr-ppar-gamma | 0.006 |
| Sr-are | 0.567 |
| Sr-atad5 | 0.016 |
| Sr-hse | 0.012 |
| Sr-mmp | 0.462 |
| Sr-p53 | 0.589 |
| Vol | 447.963 |
| Dense | 1.063 |
| Flex | 0.179 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 2 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.36 |
| Synth | 2.358 |
| Fsp3 | 0.269 |
| Mce-18 | 58.303 |
| Natural product-likeness | -1.044 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |